Schistosoma haematobium

Publication Title: 
The Journal of Infectious Diseases

Recently, artemisinin derivatives have been shown to be efficacious in chemoprophylaxis of and chemotherapy for Schistosoma japonicum and S. mansoni infections. Therefore, a double-blind, randomized, placebo-controlled study was carried out to investigate the efficacy and tolerability of artesunate plus placebo and the combination of artesunate and praziquantel in the treatment of S. haematobium infections in Gabon.

Author(s): 
Borrmann, S.
Szlezák, N.
Faucher, J. F.
Matsiegui, P. B.
Neubauer, R.
Binder, R. K.
Lell, B.
Kremsner, P. G.
Publication Title: 
PloS One

BACKGROUND: This study was conducted to determine the efficacy of the antimalarial artemisinin-based combination therapy (ACT) artesunate +sulfamethoxypyrazine/pyrimethamine (As+SMP), administered in doses used for malaria, to treat Schistosoma haematobium in school aged children. METHODOLOGY/PRINCIPAL FINDINGS: The study was conducted in Djalakorodji, a peri-urban area of Bamako, Mali, using a double blind setup in which As+SMP was compared with praziquantel (PZQ). Urine samples were examined for Schistosoma haematobium on days -1, 0, 28 and 29.

Author(s): 
Sissoko, Mahamadou S.
Dabo, Abdoulaye
Traoré, Hamidou
Diallo, Mouctar
Traoré, Boubacar
Konaté, Drissa
Niaré, Boubacar
Diakité, Moussa
Kamaté, Bourama
Traoré, Abdrahamane
Bathily, Aboudramane
Tapily, Amadou
Touré, Ousmane B.
Cauwenbergh, Sarah
Jansen, Herwig F.
Doumbo, Ogobara K.
Publication Title: 
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

BACKGROUND: Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. METHODS: We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mefloquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium.

Author(s): 
Keiser, Jennifer
N'Guessan, Nicaise A.
Adoubryn, Koffi D.
Silué, Kigbafori D.
Vounatsou, Penelope
Hatz, Christoph
Utzinger, Jürg
N'Goran, Eliézer K.
Subscribe to RSS - Schistosoma haematobium